Abstract
Monoamine oxidase B inhibitors are of particular importance in the treatment of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Herein described is pharmacophore generation and atom-based 3D-QSAR analysis of previously reported furan based MAO-B inhibitors in order to get insight into their structural requirements responsible for high affinity. The best pharmacophore model generated with the five-point hypotheses of ADHRR: hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H) and two aromatic rings (R1 & R2). On the basis of generated model, a statistically valid 3D-QSAR with good predictability was developed. Molecular docking of lead compound showed binding energy of -8.66 kcal/mol with a predicted inhibition constant of 0.448 μM towards MAO-B.
Keywords: MAO-B, 3D-QSAR, Phase, Pharmacophore, Furanochalcones.
Central Nervous System Agents in Medicinal Chemistry
Title:Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B
Volume: 16 Issue: 2
Author(s): Bijo Mathew, Sanal Dev, Jerad Suresh, Githa E. Mathew, Baskar Lakshmanan, Abitha Haridas, Fajeelath Fathima and Girish K. Krishnan
Affiliation:
Keywords: MAO-B, 3D-QSAR, Phase, Pharmacophore, Furanochalcones.
Abstract: Monoamine oxidase B inhibitors are of particular importance in the treatment of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Herein described is pharmacophore generation and atom-based 3D-QSAR analysis of previously reported furan based MAO-B inhibitors in order to get insight into their structural requirements responsible for high affinity. The best pharmacophore model generated with the five-point hypotheses of ADHRR: hydrogen bond acceptor (A), hydrogen bond donor (D), hydrophobic (H) and two aromatic rings (R1 & R2). On the basis of generated model, a statistically valid 3D-QSAR with good predictability was developed. Molecular docking of lead compound showed binding energy of -8.66 kcal/mol with a predicted inhibition constant of 0.448 μM towards MAO-B.
Export Options
About this article
Cite this article as:
Mathew Bijo, Dev Sanal, Suresh Jerad, E. Mathew Githa, Lakshmanan Baskar, Haridas Abitha, Fathima Fajeelath and K. Krishnan Girish, Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (2) . https://dx.doi.org/10.2174/1871524915666150319122540
DOI https://dx.doi.org/10.2174/1871524915666150319122540 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors
Letters in Drug Design & Discovery Book Reviews: Planting Seeds, Practicing Mindfulness with Children
Adolescent Psychiatry A Comprehensive Literature Review of COPD-Related Fatigue
Current Respiratory Medicine Reviews Modulation and Absorption of Xenobiotics: The Synergistic Role of CYP450 and P-gp Activities in Cancer and Neurodegenerative Disorders
Current Drug Metabolism Screening for Inhibitors of Microglia to Reduce Neuroinflammation
CNS & Neurological Disorders - Drug Targets Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology The Role of Cytokine Network in the Pathophysiology of Schizophrenia
Current Psychiatry Reviews A System Pharmacology Study for Deciphering Anti Depression Activity of Nardostachys jatamansi
Current Drug Metabolism Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Crosstalk Between Calpain and Calcineurin in Excitotoxic Neurodegeneration; Therapeutic Targets for the Treatment of Excitotoxic Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents Objective Assessment of the Rheological Muscle Property in the Treatment of Fibromyalgia
Endocrine, Metabolic & Immune Disorders - Drug Targets Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson’s Disease using In Silico Approach
Current Computer-Aided Drug Design Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Chronic Methylphenidate-Effects Over Circadian Cycle of Young and Adult Rats Submitted to Open-Field and Object Recognition Tests
Current Neurovascular Research Patent Selections :
Recent Patents on Cardiovascular Drug Discovery 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers
Current Radiopharmaceuticals Cannabinoids and Psychosis
Current Pharmaceutical Design